MENLO PARK, Calif.--(BUSINESS WIRE)--Ionpath, a pioneer in high-plex spatial proteomics, today announced the launch of its new service and data analysis tools for immuno-oncology applications in basic, translational, and clinical research. The service and analysis tools will be presented at the annual meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 1-5 in San Diego, in the Ionpath exhibit hall booth (#1107)..

加州门洛帕克（BUSINESS WIRE）-Ionpath是高复杂空间蛋白质组学的先驱，今天宣布推出新的服务和数据分析工具，用于基础，转化和临床研究中的免疫肿瘤学应用。服务和分析工具将于11月1日至5日在圣地亚哥举行的癌症免疫治疗学会（SITC）年会上在Ionpath展览厅（＃1107）上展示。。

Ionpath’s single-cell, spatial proteomics service utilizes its multiplexed ion beam imaging (MIBI™) technology, which uses mass spectrometry to query dozens of proteins with unmatched sensitivity and true subcellular resolution. The service offering, known as MIBIplus, launches with a human immuno-oncology panel that enables the detection of more than 40 relevant cell types in a single scan for a more complete view of the biological mechanisms in the tissue microenvironment affecting drug response, cancer progression, and more.

Ionpath的单细胞空间蛋白质组学服务利用其多路复用离子束成像（MIBI）™) 该技术使用质谱技术以无与伦比的灵敏度和真正的亚细胞分辨率查询数十种蛋白质。这项名为MIBIplus的服务推出了一个人体免疫肿瘤学小组，可以在一次扫描中检测40多种相关细胞类型，以更全面地了解影响药物反应的组织微环境中的生物学机制，癌症进展等等。

Tissue samples are processed and run at Ionpath, and data is analyzed and returned to clients through a standardized report of actionable information. Ionpath’s new user-friendly analysis tool, MIBIsight, allows for iteration and customization of the standardized report by the customer to answer specific research questions..

在Ionpath处理和运行组织样本，分析数据并通过可操作信息的标准化报告返回给客户。Ionpath新的用户友好型分析工具MIBIsight允许客户迭代和定制标准化报告以回答特定的研究问题。。

“We’ve heard customers express high interest in a way to convert raw image data into actionable insights,” said David Summa, CEO of Ionpath. “In response, we are launching a new service offering, with user-friendly bioinformatic tools enabling scientists to take control of their data interpretation.”.

Ionpath首席执行官David Summa说：“我们听说客户对将原始图像数据转换为可行的见解表示高度兴趣。“作为回应，我们正在推出一项新服务，提供用户友好的生物信息学工具，使科学家能够控制他们的数据解释。”。

The MIBIplus immuno-oncology service is now available for human tissue samples, and will soon be available for mouse samples as well. Projects can be completed from start to finish in two months or less. Special introductory pricing is available for new clients interested in learning how MIBI technology works with their samples through pilot projects..

MIBIplus免疫肿瘤学服务现已用于人体组织样本，并将很快用于小鼠样本。项目可以在两个月或更短的时间内从开始到结束完成。对于有兴趣通过试点项目了解MIBI技术如何与样品一起工作的新客户，可以提供特殊的介绍性定价。。

To learn more about the immuno-oncology service, please visit our SITC booth (#1107) or our website: https://www.ionpath.com/mibiplus/.

要了解有关免疫肿瘤学服务的更多信息，请访问我们的SITC展位（＃1107）或我们的网站：https://www.ionpath.com/mibiplus/.

About Ionpath

关于离子路径

Ionpath, Inc., is a pioneer in high-definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate medical discovery and improve human health. Ionpath’s MIBI™ (multiplexed ion beam imaging) platform breaks through the limitations of traditional immunohistochemistry, enabling a deeper understanding of the tissue microenvironment with highly multiplexed, quantitative single-cell analysis.

Ionpath公司是高清空间蛋白质组学的先驱，它彻底改变组织成像和分析，加速医学发现和改善人类健康。Ionpath的MIBI™ （多重离子束成像）平台突破了传统免疫组织化学的局限性，通过高度多重，定量的单细胞分析可以更深入地了解组织微环境。

With MIBI technology and the expertise of world-class pathology and data science teams, Ionpath provides actionable insights for translational and clinical researchers at leading pharmaceutical, biotechnology, and research organizations in immuno-oncology, immunology, neuroscience, and infectious disease research..

凭借MIBI技术和世界级病理学和数据科学团队的专业知识，Ionpath为免疫肿瘤学，免疫学，神经科学和传染病研究领域的领先制药，生物技术和研究机构的转化和临床研究人员提供了可行的见解。。